Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

High-Throughput Mutation Profiling of Primary and Metastatic Endometrial Cancers Identifies KRAS, FGFR2 and PIK3CA to Be Frequently Mutated

27 Dec 2012

Abstract excerpt

BACKGROUND: Despite being the most common pelvic gynecologic malignancy in industrialized countries, no targeted therapies are available for patients with metastatic endometrial carcinoma. In order to improve treatment, underlying molecular characteristics of primary and metastatic disease must be explored. METHODOLOGY/PRINCIPAL FINDINGS: We utilized the mass spectrometric-based mutation detection technology...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Genomics and Diagnostics
Share to Endometrial and Cervical Cancer Treatments
Share to Fibroblast Growth Factor Research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 23300780
DOI: 10.1371/journal.pone.0052795

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

High-Throughput Mutation Profiling of Primary and Metastatic Endometrial Cancers Identifies KRAS, FGFR2 and PIK3CA to Be Frequently MutatedPMID 23300780Read ↗

Designing a High-Throughput Somatic Mutation Profiling Panel Specifically for Gynaecological CancersSemantic proximity Read ↗

Clinical Relevance of Oncogenic Driver Mutations Identified in Endometrial CarcinomaSemantic proximity Read ↗

KRAS gene amplification and overexpression but not mutation associates with aggressive and metastatic endometrial cancer.Semantic proximity Read ↗

Met Mutation is a Potential Therapeutic Target for Advanced Endometrial Cancer Semantic proximity Read ↗

Clinical relevance of oncogenic driver mutations identified in endometrial carcinomaSemantic proximity Read ↗

KRAS mutations in endometrial cancers: Possible prognostic and treatment implications.Semantic proximity Read ↗

Clinical and Genomic Landscape of RAS Mutations in Gynecologic Cancers.Semantic proximity Read ↗

FGFR2 point mutations in 466 endometrioid endometrial tumors: relationship with MSI, KRAS, PIK3CA, CTNNB1 mutations and clinicopathological features.Semantic proximity Read ↗

Whole-exome sequencing combined with functional genomics reveals novel candidate driver cancer genes in endometrial cancer.Semantic proximity Read ↗

Mutations in cancer-relevant genes are ubiquitous in histologically normal endometrial tissue.Semantic proximity Read ↗

Molecular profiling of endometrial carcinoma precursor, primary and metastatic lesions suggests different targets for treatment in obese compared to non-obese patients.Semantic proximity Read ↗

Tissue-specific signatures of activating PIK3CA and RAS mutations in carcinosarcomas of gynecologic origin.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.